These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20017888)

  • 1. Rituximab treatment in rheumatoid arthritis: how does it work?
    Boumans MJ; Tak PP
    Arthritis Res Ther; 2009; 11(6):134. PubMed ID: 20017888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
    Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
    Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
    Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
    Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good and bad memories following rituximab therapy.
    St Clair EW
    Arthritis Rheum; 2010 Jan; 62(1):1-5. PubMed ID: 20039422
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
    Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
    Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
    Dass S; Vital EM; Emery P
    Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
    Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
    Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
    Shaw T; Quan J; Totoritis MC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
    [No Abstract]   [Full Text] [Related]  

  • 10. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
    Vital EM; Dass S; Rawstron AC; Buch MH; Goëb V; Henshaw K; Ponchel F; Emery P
    Arthritis Rheum; 2010 May; 62(5):1273-9. PubMed ID: 20131284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab treatment of rheumatoid arthritis: new evidence].
    Nasonov EL
    Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B lymphocyte-typing for prediction of clinical response to rituximab.
    Brezinschek HP; Rainer F; Brickmann K; Graninger WB
    Arthritis Res Ther; 2012 Jul; 14(4):R161. PubMed ID: 22770118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P; Jamin C; Saraux A
    Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-CD20 antibody therapy for inflammatory immune diseases].
    Tanaka Y
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
    [No Abstract]   [Full Text] [Related]  

  • 17. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell-directed therapies for autoimmune disease.
    Dörner T; Radbruch A; Burmester GR
    Nat Rev Rheumatol; 2009 Aug; 5(8):433-41. PubMed ID: 19581902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.
    Trouvin AP; Jacquot S; Grigioni S; Curis E; Dedreux I; Roucheux A; Boulard H; Vittecoq O; Le Loët X; Boyer O; Goëb V
    Clin Exp Immunol; 2015 Apr; 180(1):11-8. PubMed ID: 25370437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.